

Nancy Y Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8638669/publications.pdf>

Version: 2024-02-01

323
papers

27,255
citations

11235

73
h-index

8212

153
g-index

333
all docs

333
docs citations

333
times ranked

25768
citing authors

#	ARTICLE	IF	CITATIONS
1	Proton beam radiation therapy treatment for head and neck cancer. <i>Precision Radiation Oncology</i> , 2022, 6, 59-68.	0.4	9
2	Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial. <i>Radiotherapy and Oncology</i> , 2022, 167, 179-186.	0.3	8
3	Prospectively-validated deep learning model for segmenting swallowing and chewing structures in CT. <i>Physics in Medicine and Biology</i> , 2022, 67, 024001.	1.6	13
4	Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus-Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. <i>JAMA Oncology</i> , 2022, 8, 364.	3.4	39
5	Influence of Treatment Package Time on outcomes in High-Risk Oral Cavity Carcinoma in patients receiving Adjuvant Radiation and Concurrent Systemic Therapy: A Multi-Institutional Oral Cavity Collaborative study. <i>Oral Oncology</i> , 2022, 126, 105781.	0.8	3
6	Primary chondrosarcomas of the larynx treated with proton radiotherapy: A single institutional experience. <i>Cancer Reports</i> , 2022, , e1621.	0.6	1
7	A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2022, 32, 799-806.	2.4	4
8	Implementation Strategies to Increase Clinical Trial Enrollment in a Community-Academic Partnership and Impact on Hispanic Representation: An Interrupted Time Series Analysis. <i>JCO Oncology Practice</i> , 2022, 18, e780-e785.	1.4	11
9	Well-Differentiated Thyroid Cancer: Who Should Get Postoperative Radiation?. <i>Annals of Surgical Oncology</i> , 2022, , .	0.7	0
10	Outcomes and Toxicities of Nonmedullary Thyroid Tumors Treated with Proton Beam Radiation Therapy. <i>International Journal of Particle Therapy</i> , 2022, 9, 20-30.	0.9	0
11	Randomized Phase II Trial of Proton Craniospinal Irradiation Versus Photon Involved-Field Radiotherapy for Patients With Solid Tumor Leptomeningeal Metastasis. <i>Journal of Clinical Oncology</i> , 2022, 40, 3858-3867.	0.8	47
12	Evaluating compliance with process-related quality metrics and survival in oral cavity squamous cell carcinoma: Multi-institutional oral cavity collaboration study. <i>Head and Neck</i> , 2021, 43, 60-69.	0.9	4
13	Pathogenic <i>ATM</i> Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 266-273.	3.0	38
14	High-Dose Chemoradiation Irrespective of Age. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 11-12.	0.4	0
15	The head and neck cancer genome in the era of immunotherapy. <i>Oral Oncology</i> , 2021, 112, 105040.	0.8	13
16	Atypical metastasis of nasopharyngeal cancer: noncontiguous spread to the ipsilateral ear. <i>Clinical Imaging</i> , 2021, 72, 70-74.	0.8	1
17	Case study of the integration of electronic patient-reported outcomes as standard of care in a head and neck oncology practice: Obstacles and opportunities. <i>Cancer</i> , 2021, 127, 359-371.	2.0	10
18	Randomized Phase II Trial of Nivolumab With Stereotactic Body Radiotherapy Versus Nivolumab Alone in Metastatic Head and Neck Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 30-37.	0.8	239

#	ARTICLE	IF	CITATIONS
19	Precision Radiotherapy: Reduction in Radiation for Oropharyngeal Cancer in the 30 ROC Trial. Journal of the National Cancer Institute, 2021, 113, 742-751.	3.0	98
20	Javelin Head Neck 100: Should we combine immunotherapy with radiation therapy?. Oncotarget, 2021, 12, 2223-2226.	0.8	12
21	Intensity-Modulated Radiation Therapy for Nasopharyngeal Cancer. Practical Guides in Radiation Oncology, 2021, , 71-81.	0.0	0
22	Can the Risk of Dysphagia in Head and Neck Radiation Therapy Be Predicted by an Automated Transit Fluence Monitoring Process During Treatment? A First Comparative Study of Patient Reported Quality of Life and the Fluence-Based Decision Support Metric. Technology in Cancer Research and Treatment, 2021, 20, 153303382110279.	0.8	2
23	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nature Communications, 2021, 12, 729.	5.8	212
24	Outcomes and prognostic factors of major salivary gland tumors treated with proton beam radiation therapy. Head and Neck, 2021, 43, 1056-1062.	0.9	11
25	Any day, split halfway: Flexibility in scheduling high-dose cisplatin—A large retrospective review from a high-volume cancer center. International Journal of Cancer, 2021, 149, 139-148.	2.3	1
26	Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 840-859.	0.8	178
27	Nongaussian Intravoxel Incoherent Motion Diffusion Weighted and Fast Exchange Regime Dynamic Contrast-Enhanced-MRI of Nasopharyngeal Carcinoma: Preliminary Study for Predicting Locoregional Failure. Cancers, 2021, 13, 1128.	1.7	4
28	The hidden curve behind COVID-19 outbreak: the impact of delay in treatment initiation in cancer patients and how to mitigate the additional risk of dying—the head and neck cancer model. Cancer Causes and Control, 2021, 32, 459-471.	0.8	11
29	Treatment Deescalation Strategies for Nasopharyngeal Cancer. JAMA Oncology, 2021, 7, 445.	3.4	18
30	Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. Lancet Oncology, The, 2021, 22, 450-462.	5.1	287
31	Reproducibility of radiomic features using network analysis and its application in Wasserstein k-means clustering. Journal of Medical Imaging, 2021, 8, 031904.	0.8	1
32	Comparison of FDG and FMISO uptakes and distributions in head and neck squamous cell cancer tumors. EJNMMI Research, 2021, 11, 38.	1.1	6
33	Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).. Journal of Clinical Oncology, 2021, 39, 6060-6060.	0.8	1
34	Tumor Immunity and Immunotherapy for HPV-Related Cancers. Cancer Discovery, 2021, 11, 1896-1912.	7.7	71
35	The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.. Journal of Clinical Oncology, 2021, 39, 6019-6019.	0.8	8
36	Public access to protocols of contemporary cancer randomized clinical trials. Trials, 2021, 22, 418.	0.7	5

#	ARTICLE	IF	CITATIONS
37	A Systematic Review of Proton Therapy for the Management of Nasopharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 119-130.	0.9	11
38	Outcomes of Post-Operative Treatment with Concurrent Chemoradiotherapy (CRT) in High-Risk Resected Oral Cavity Squamous Cell Carcinoma (OCSCC): A Multi-Institutional Collaboration. <i>Current Oncology</i> , 2021, 28, 2409-2419.	0.9	8
39	Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. <i>Cancer Medicine</i> , 2021, 10, 4221-4227.	1.3	8
40	Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers. <i>International Journal of Particle Therapy</i> , 2021, 8, 248-260.	0.9	2
41	Work Outcomes after Intensity-Modulated Proton Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for Oropharyngeal Cancer. <i>International Journal of Particle Therapy</i> , 2021, 8, 319-327.	0.9	11
42	Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Nasopharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. <i>JAMA Network Open</i> , 2021, 4, e2113205.	2.8	34
43	Re-irradiation versus surgery for locally recurrent nasopharyngeal carcinoma. <i>Lancet Oncology</i> , The, 2021, 22, e218.	5.1	2
44	Intensity-modulated radiation therapy and doxorubicin in thyroid cancer: A prospective phase 2 trial. <i>Cancer</i> , 2021, 127, 4161-4170.	2.0	8
45	International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 682-695.	0.4	42
46	Patient selection for immunotherapy in head and neck cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2021, 22, e291-e292.	5.1	0
47	<i>TERT</i> Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. <i>JCO Precision Oncology</i> , 2021, 5, 1259-1269.	1.5	10
48	Application of Community Detection Algorithm to Investigate the Correlation between Imaging Biomarkers of Tumor Metabolism, Hypoxia, Cellularity, and Perfusion for Precision Radiotherapy in Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 3908.	1.7	3
49	Can Radiation Therapy Quality Assurance Improve Nasopharyngeal Cancer Outcomes in Low- and Middle-Income Countries: Reporting the First Phase of a Prospective International Atomic Energy Agency Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1227-1236.	0.4	5
50	The effect of short radiation treatment breaks on chemo-radiotherapy for oropharyngeal cancers. <i>Head and Neck</i> , 2021, 43, 3796-3809.	0.9	0
51	HPV-associated oropharyngeal cancer de-escalation strategies and trials: Past failures and future promise. <i>Journal of Surgical Oncology</i> , 2021, 124, 962-966.	0.8	12
52	Current considerations for radiotherapy in HPV-associated head and neck cancer. <i>Journal of Surgical Oncology</i> , 2021, 124, 945-951.	0.8	3
53	Outcomes following head and neck cancer surgery among older adults as determined by an electronic geriatric assessment. <i>Journal of Geriatric Oncology</i> , 2021, , .	0.5	4
54	Patterns of Radiotherapy Use and Outcomes in Head and Neck Soft-Tissue Sarcoma in a National Cohort. <i>Laryngoscope</i> , 2020, 130, 120-127.	1.1	5

#	ARTICLE	IF	CITATIONS
55	Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. <i>Cancer</i> , 2020, 126, 444-452.	2.0	38
56	Outcomes of surgery and postoperative radiation therapy in managing medullary thyroid carcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 234-243.	0.8	4
57	A Phase 1b Study of Cetuximab and BYL719 (Alpelisib) Concurrent with Intensity Modulated Radiation Therapy in Stage III-IVB Head and Neck Squamous Cell Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 564-570.	0.4	51
58	Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. <i>International Journal of Cancer</i> , 2020, 147, 107-115.	2.3	14
59	<i>Cancer of the Head and Neck</i> , 2020, , 999-1033.e7.		3
60	Practice recommendations for risk-adapted head and neck cancer radiotherapy during the COVID-19 pandemic: An ASTRO-ESTRO consensus statement. <i>Radiotherapy and Oncology</i> , 2020, 151, 314-321.	0.3	24
61	Past, present and future of proton therapy for head and neck cancer. <i>Oral Oncology</i> , 2020, 110, 104879.	0.8	22
62	The Importance of Locoregional Therapy in Metastatic Nasopharyngeal Cancer. <i>JAMA Oncology</i> , 2020, 6, 1353.	3.4	4
63	Update of Radiation Techniques Using Photons for Anterior Skull Base Tumors. <i>Advances in Oto-Rhino-Laryngology</i> , 2020, 84, 68-77.	1.6	1
64	Postoperative Radiation Therapy to Pathologically Negative Neck Nodal Stations in Patients With Indications for Radiation Therapy at the Primary Site. <i>Practical Radiation Oncology</i> , 2020, 10, 383-385.	1.1	2
65	An imbalance in competing mortality favouring Debio 1143. <i>Lancet Oncology</i> , The, 2020, 21, e502.	5.1	2
66	Non-invasive imaging prediction of tumor hypoxia: A novel developed and externally validated CT and FDG-PET-based radiomic signatures. <i>Radiotherapy and Oncology</i> , 2020, 153, 97-105.	0.3	19
67	Prognostic significance of human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma. <i>Head and Neck</i> , 2020, 42, 2364-2374.	0.9	12
68	Beyond reirradiation: Efficacy and safety of three or more courses of radiation for head and neck malignancies. <i>Clinical and Translational Radiation Oncology</i> , 2020, 23, 30-34.	0.9	2
69	Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. <i>Cancer</i> , 2020, 126, 3900-3906.	2.0	62
70	Is It Worth It? Consequences of Definitive Head and Neck Reirradiation. <i>Seminars in Radiation Oncology</i> , 2020, 30, 212-217.	1.0	5
71	To Shy Away From Chemotherapy Is to Compromise. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 616-617.	0.4	0
72	Nasopharynx cancer: Induction or adjuvant? That is the question. <i>Cancer</i> , 2020, 126, 3620-3623.	2.0	1

#	ARTICLE	IF	CITATIONS
73	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 253-261.	1.0	18
74	Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. <i>Oral Oncology</i> , 2020, 104, 104641.	0.8	16
75	The 3 Bs of cancer care amid the COVID-19 pandemic crisis: "Be safe, be smart, be kind" A multidisciplinary approach increasing the use of radiation and embracing telemedicine for head and neck cancer. <i>Cancer</i> , 2020, 126, 4092-4104.	2.0	24
76	Offline Quality Assurance for Intensity Modulated Radiation Therapy Treatment Plans for NRG-HN001 Head and Neck Clinical Trial Using Knowledge-Based Planning. <i>Advances in Radiation Oncology</i> , 2020, 5, 1342-1349.	0.6	15
77	Radiomic analysis identifies tumor subtypes associated with distinct molecular and microenvironmental factors in head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 104877.	0.8	22
78	Outcomes and toxicities of definitive radiotherapy and reirradiation using 3-dimensional conformal or intensity-modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. <i>Cancer</i> , 2020, 126, 1905-1916.	2.0	31
79	Clinical outcomes, local-regional control and the role for metastasis-directed therapies in stage III non-small cell lung cancers treated with chemoradiation and durvalumab. <i>Radiotherapy and Oncology</i> , 2020, 149, 205-211.	0.3	39
80	Safety and Feasibility of PARP1/2 Imaging with 18F-PARPi in Patients with Head and Neck Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3110-3116.	3.2	36
81	Practice Recommendations for Risk-Adapted Head and Neck Cancer Radiation Therapy During the COVID-19 Pandemic: An ASTRO-ESTRO Consensus Statement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 618-627.	0.4	156
82	Temporal Lobe Necrosis in Head and Neck Cancer Patients after Proton Therapy to the Skull Base. <i>International Journal of Particle Therapy</i> , 2020, 6, 17-28.	0.9	24
83	Computational Modeling of Interstitial Fluid Pressure and Velocity in Head and Neck Cancer Based on Dynamic Contrast-Enhanced Magnetic Resonance Imaging: Feasibility Analysis. <i>Tomography</i> , 2020, 6, 129-138.	0.8	14
84	Salvage surgery for recurrent larynx cancer. <i>Head and Neck</i> , 2019, 41, 3906-3915.	0.9	22
85	Predicting radiation dosimetric distribution in different regions of the jaw in patients receiving radiotherapy for squamous cell carcinoma of the tonsil. <i>Head and Neck</i> , 2019, 41, 3604-3611.	0.9	5
86	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). , 2019, 7, 184.		413
87	Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. <i>Head and Neck</i> , 2019, 41, 3551-3563.	0.9	16
88	Optimal mass transport kinetic modeling for head and neck DCE-MRI: Initial analysis. <i>Magnetic Resonance in Medicine</i> , 2019, 82, 2314-2325.	1.9	3
89	Human papillomavirus 16 promotes microhomology-mediated end-joining. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 21573-21579.	3.3	57
90	Long-term survival in patients with metastatic head and neck squamous cell carcinoma treated with metastasis-directed therapy. <i>British Journal of Cancer</i> , 2019, 121, 897-903.	2.9	32

#	ARTICLE	IF	CITATIONS
91	International Guideline on Dose Prioritization and Acceptance Criteria in Radiation Therapy Planning for Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 567-580.	0.4	96
92	Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2019, 111, 655-663.	3.0	56
93	The repertoire of genetic alterations in salivary duct carcinoma including a novel HNRNP3-ALK rearrangement. <i>Human Pathology</i> , 2019, 88, 66-77.	1.1	38
94	Organ preservation for patients with anterior mucosal squamous cell carcinoma of the nasal cavity: Rhinectomy-free survival in those refusing surgery. <i>Head and Neck</i> , 2019, 41, 2741-2747.	0.9	11
95	A competing risk nomogram to predict severe late toxicity after modern re-irradiation for squamous carcinoma of the head and neck. <i>Oral Oncology</i> , 2019, 90, 80-86.	0.8	26
96	Hypoxia with 18F-fluoroerythronitroimidazole integrated positron emission tomography and computed tomography (18F-FETNIM PET/CT) in locoregionally advanced head and neck cancer. <i>Medicine (United States)</i> , 2019, 98, e17067.	0.4	16
97	Endoscopic Resection Followed by Proton Therapy With Pencil Beam Scanning for Skull Base Tumors. <i>Laryngoscope</i> , 2019, 129, 1313-1317.	1.1	2
98	Reducing the Radiation Therapy Dose Prescription for Elective Treatment Areas in Human Papillomavirus-associated Oropharyngeal Carcinoma Being Treated With Primary Chemoradiotherapy at Memorial Sloan Kettering Cancer Center. <i>Practical Radiation Oncology</i> , 2019, 9, 98-101.	1.1	23
99	JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer. <i>Future Oncology</i> , 2019, 15, 687-694.	1.1	41
100	Comparing Kadish, TNM, and the modified Dulguerov staging systems for esthesioneuroblastoma. <i>Journal of Surgical Oncology</i> , 2019, 119, 130-142.	0.8	40
101	Tumor mutational load predicts survival after immunotherapy across multiple cancer types. <i>Nature Genetics</i> , 2019, 51, 202-206.	9.4	2,702
102	Treatment modalities and outcomes of Fanconi anemia patients with head and neck squamous cell carcinoma: Series of 9 cases and review of the literature. <i>Head and Neck</i> , 2019, 41, 1418-1426.	0.9	21
103	Pilot study combining PD-L1 antibody durvalumab (D) with CTLA-4 antibody tremelimumab (T) and stereotactic body radiotherapy (SBRT) to treat metastatic anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 6088-6088.	0.8	9
104	Trends and Disparities of Proton Therapy Use among Patients with Head and Neck Cancer: Analysis from the National Cancer Database (2005-14). <i>International Journal of Particle Therapy</i> , 2019, 5, 1-10.	0.9	10
105	Repeatability of Quantitative Diffusion-Weighted Imaging Metrics in Phantoms, Head-and-Neck and Thyroid Cancers: Preliminary Findings. <i>Tomography</i> , 2019, 5, 15-25.	0.8	20
106	Patterns of recurrence in oral tongue cancer with perineural invasion. <i>Head and Neck</i> , 2018, 40, 1287-1295.	0.9	73
107	Long-term outcomes in oral cavity squamous cell carcinoma with adjuvant and salvage radiotherapy after surgery. <i>Laryngoscope</i> , 2018, 128, 2539-2545.	1.1	16
108	Head and neck cancers associated with exposure to the September 11, 2001 World Trade Center terrorist attacks. <i>International Journal of Cancer</i> , 2018, 142, 2485-2490.	2.3	7

#	ARTICLE	IF	CITATIONS
109	Chromosomal instability drives metastasis through a cytosolic DNA response. <i>Nature</i> , 2018, 553, 467-472.	13.7	1,002
110	Predicting hypoxia status using a combination of contrast-enhanced computed tomography and [18F]-Fluorodeoxyglucose positron emission tomography radiomics features. <i>Radiotherapy and Oncology</i> , 2018, 127, 36-42.	0.3	55
111	Salivary Gland Tumors. <i>Practical Guides in Radiation Oncology</i> , 2018, , 153-163.	0.0	0
112	Volume, Dose, and Fractionation Considerations for IMRT-based Reirradiation in Head and Neck Cancer: A Multi-institution Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 606-617.	0.4	68
113	Tumors of the Nasopharynx. <i>Practical Guides in Radiation Oncology</i> , 2018, , 107-116.	0.0	0
114	Oral Cavity Tumors. <i>Practical Guides in Radiation Oncology</i> , 2018, , 117-130.	0.0	0
115	A Multi-institutional Comparison of SBRT and IMRT for Definitive Reirradiation of Recurrent or Second Primary Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 595-605.	0.4	101
116	Refining Patient Selection for Reirradiation of Head and Neck Squamous Carcinoma in the IMRT Era: A Multi-institution Cohort Study by the MIRI Collaborative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 586-594.	0.4	105
117	Facility Volume and Survival in Nasopharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 408-417.	0.4	37
118	Proton Therapy for Head and Neck Cancers. <i>Seminars in Radiation Oncology</i> , 2018, 28, 53-63.	1.0	89
119	International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. <i>Radiotherapy and Oncology</i> , 2018, 126, 25-36.	0.3	214
120	Long-term quality of life in older patients with HPV-related oropharyngeal cancer. <i>Head and Neck</i> , 2018, 40, 2321-2328.	0.9	6
121	Characteristics of Radiotherapy Trials Compared With Other Oncological Clinical Trials in the Past 10 Years. <i>JAMA Oncology</i> , 2018, 4, 1073.	3.4	44
122	Parotid gland fat related Magnetic Resonance image biomarkers improve prediction of late radiation-induced xerostomia. <i>Radiotherapy and Oncology</i> , 2018, 128, 459-466.	0.3	69
123	Validation and assessment of discordance of the 8th edition AJCC (American Joint Committee on) Tj ETQq1 1 0.784314 rgBT /Overl with surgery and adjuvant radiation at a single institution. <i>Oral Oncology</i> , 2018, 83, 140-146.	0.8	8
124	Image-based Data Mining to Probe Dosimetric Correlates of Radiation-induced Trismus. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1330-1338.	0.4	32
125	Proton Therapy for Head and Neck Cancer. <i>Current Treatment Options in Oncology</i> , 2018, 19, 28.	1.3	46
126	Comparing Intensity-Modulated Proton Therapy With Intensity-Modulated Photon Therapy for Oropharyngeal Cancer: The Journey From Clinical Trial Concept to Activation. <i>Seminars in Radiation Oncology</i> , 2018, 28, 108-113.	1.0	26

#	ARTICLE	IF	CITATIONS
127	The therapeutic significance of mutational signatures from DNA repair deficiency in cancer. <i>Nature Communications</i> , 2018, 9, 3292.	5.8	153
128	Intensity-Modulated Radiation Therapy With or Without Concurrent Chemotherapy in Nonanaplastic Thyroid Cancer with Unresectable or Gross Residual Disease. <i>Thyroid</i> , 2018, 28, 1180-1189.	2.4	23
129	Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot. <i>International Journal of Particle Therapy</i> , 2018, 4, 10-19.	0.9	9
130	Internal and external generalizability of temporal dose-response relationships for xerostomia following IMRT for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 200-206.	0.3	5
131	The role of parotid gland irradiation in the development of severe hyposalivation (xerostomia) after intensity-modulated radiation therapy for head and neck cancer: Temporal patterns, risk factors, and testing the QUANTEC guidelines. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2017, 45, 595-600.	0.7	24
132	Patient Reflections on Decision Making for Laryngeal Cancer Treatment. <i>Otolaryngology - Head and Neck Surgery</i> , 2017, 156, 299-304.	1.1	47
133	Multiparametric Imaging of Tumor Hypoxia and Perfusion with ¹⁸ F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1072-1080.	2.8	31
134	Patterns of Care in Adjuvant Therapy for Resected Oral Cavity Squamous Cell Cancer in Elderly Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 758-766.	0.4	7
135	Re-Irradiation Therapy for Locally Recurrent Head and Neck Cancer: A National Survey of Practice Patterns. <i>Cancer Investigation</i> , 2017, 35, 393-402.	0.6	3
136	A magnetic resonance imaging-based approach to quantify radiation-induced normal tissue injuries applied to trismus in head and neck cancer. <i>Physics and Imaging in Radiation Oncology</i> , 2017, 1, 34-40.	1.2	26
137	Proton therapy for head and neck cancer: expanding the therapeutic window. <i>Lancet Oncology</i> , The, 2017, 18, e254-e265.	5.1	106
138	Survey of current practices from the International Stereotactic Body Radiotherapy Consortium (ISBRTC) for head and neck cancers. <i>Future Oncology</i> , 2017, 13, 603-613.	1.1	31
139	Patterns of Treatment Failure and Postrecurrence Outcomes Among Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma After Chemoradiotherapy Using Modern Radiation Techniques. <i>JAMA Oncology</i> , 2017, 3, 1487.	3.4	146
140	Predictive modeling of outcomes following definitive chemoradiotherapy for oropharyngeal cancer based on FDG-PET image characteristics. <i>Physics in Medicine and Biology</i> , 2017, 62, 5327-5343.	1.6	51
141	In Reply to Pareek. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 437-438.	0.4	0
142	Long-term local control rates of patients with adenoid cystic carcinoma of the head and neck managed by surgery and postoperative radiation. <i>Laryngoscope</i> , 2017, 127, 2265-2269.	1.1	49
143	The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience. <i>Oral Oncology</i> , 2017, 64, 44-51.	0.8	159
144	Impact of concomitant chemoradiation on survival for patients with T1N1 head and neck cancer. <i>Cancer</i> , 2017, 123, 1555-1565.	2.0	12

#	ARTICLE	IF	CITATIONS
145	The toxicity and efficacy of concomitant chemoradiotherapy in patients aged 70 years and older with oropharyngeal carcinoma in the intensity-modulated radiotherapy era. <i>Cancer</i> , 2017, 123, 1345-1353.	2.0	20
146	Intravoxel incoherent motion diffusion-weighted MRI during chemoradiation therapy to characterize and monitor treatment response in human papillomavirus head and neck squamous cell carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 45, 1013-1023.	1.9	50
147	Association of Surgical Approach and Margin Status With Oncologic Outcomes Following Gross Total Resection for Sinonasal Melanoma. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1220.	1.2	27
148	Combined high-intensity local treatment and systemic therapy in metastatic head and neck squamous cell carcinoma: An analysis of the National Cancer Data Base. <i>Cancer</i> , 2017, 123, 4583-4593.	2.0	23
149	Association of Number of Dissected Lymph Nodes With Survival in Clinically Node-Negative Oral Cavity Squamous Cell Carcinoma Patients Undergoing Primary Surgery. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2017, 143, 1049.	1.2	15
150	Monitoring early response to chemoradiotherapy with 18F-FMISO dynamic PET in head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1682-1691.	3.3	33
151	Adjuvant radiation in the TORS era: Is there a benefit to omitting the tumor bed?. <i>Practical Radiation Oncology</i> , 2017, 7, 93-99.	1.1	18
152	Sparing of high retropharyngeal nodal basins in patients with unilateral oropharyngeal carcinoma treated with intensity modulated radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, 254-259.	1.1	17
153	The Molecular Landscape of Recurrent and Metastatic Head and Neck Cancers. <i>JAMA Oncology</i> , 2017, 3, 244.	3.4	191
154	Patterns of nodal failure after intensity modulated radiotherapy for nasopharyngeal carcinoma. <i>Laryngoscope</i> , 2017, 127, 377-382.	1.1	16
155	A personalized approach using hypoxia resolution to guide curative-intent radiation dose-reduction to 30 Gy: A novel de-escalation paradigm for HPV-associated oropharynx cancers (OPC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 6076-6076.	0.8	8
156	Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in <i>ATM</i> . <i>Oncotarget</i> , 2017, 8, 10312-10323.	0.8	31
157	Recurrent/Metastatic Head and Neck Cancer: When and How to Irradiate. , 2017, , 209-219.		0
158	Hypopharyngeal squamous cell carcinoma: Three-dimensional or Intensity-modulated radiotherapy? A single institution's experience. <i>Laryngoscope</i> , 2016, 126, 620-626.	1.1	16
159	Trends in chemoradiation use in elderly patients with head and neck cancer: Changing treatment patterns with cetuximab. <i>Head and Neck</i> , 2016, 38, E165-71.	0.9	26
160	Patterns of regional and distant metastasis in esthesioneuroblastoma. <i>Laryngoscope</i> , 2016, 126, 1556-1561.	1.1	57
161	Impact of elective neck dissection on the outcome of oral squamous cell carcinomas arising in the maxillary alveolus and hard palate. <i>Head and Neck</i> , 2016, 38, E1688-94.	0.9	28
162	Localized sinonasal mucosal melanoma: Outcomes and associations with stage, radiotherapy, and positron emission tomography response. <i>Head and Neck</i> , 2016, 38, 1310-1317.	0.9	65

#	ARTICLE	IF	CITATIONS
163	Concurrent Chemoradiotherapy With Cisplatin Versus Cetuximab for Squamous Cell Carcinoma of the Head and Neck. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 27-31.	0.6	58
164	Objective assessment of trismus in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT). <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2016, 44, 1408-1413.	0.7	26
165	External-beam radiotherapy for differentiated thyroid cancer locoregional control: A statement of the American Head and Neck Society. <i>Head and Neck</i> , 2016, 38, 493-498.	0.9	76
166	Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent. <i>Scientific Reports</i> , 2016, 6, 21371.	1.6	58
167	Neck spasms: A late sequela of head and neck irradiation. <i>Oral Oncology</i> , 2016, 57, e4-e5.	0.8	1
168	Postoperative PET/CT and target delineation before adjuvant radiotherapy in patients with oral cavity squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E1285-93.	0.9	17
169	Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2016, 122, 566-571.	0.2	18
170	Cervical nodal level V can safely be omitted in the treatment of locally advanced oropharyngeal squamous cell carcinoma with definitive IMRT. <i>Oral Oncology</i> , 2016, 58, 27-31.	0.8	8
171	Impact of Flap Reconstruction on Radiotoxicity After Salvage Surgery and Reirradiation for Recurrent Head and Neck Cancer. <i>Annals of Surgical Oncology</i> , 2016, 23, 850-857.	0.7	9
172	High-dose hypofractionated radiotherapy is effective and safe for tumors in the head-and-neck. <i>Oral Oncology</i> , 2016, 60, 74-80.	0.8	11
173	Incidence of Oropharyngeal Cancer Among Elderly Patients in the United States. <i>JAMA Oncology</i> , 2016, 2, 1617.	3.4	114
174	Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer. <i>Cancers of the Head & Neck</i> , 2016, 1, 4.	6.2	19
175	Phase II trial of bevacizumab+cetuximab+cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2016, 38, E566-70.	0.9	35
176	Strategy of Using Intratreatment Hypoxia Imaging to Selectively and Safely Guide Radiation Dose De-escalation Concurrent With Chemotherapy for Locoregionally Advanced Human Papillomavirus-Related Oropharyngeal Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 9-17.	0.4	121
177	Proton Beam Reirradiation for Recurrent Head and Neck Cancer: Multi-institutional Report on Feasibility and Early Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 386-395.	0.4	132
178	Intensity-modulated radiotherapy for head and neck surgeons. <i>Head and Neck</i> , 2016, 38, E2368-73.	0.9	24
179	Safety of contralateral submandibular gland sparing in locally advanced oropharyngeal cancers: A multicenter review. <i>Head and Neck</i> , 2016, 38, 506-511.	0.9	13
180	Patterns of failure in patients with head and neck carcinoma of unknown primary treated with radiation therapy. <i>Head and Neck</i> , 2016, 38, E426-31.	0.9	16

#	ARTICLE	IF	CITATIONS
181	Taselisib (GDC-0032), a Potent Î²-Sparing Small Molecule Inhibitor of PI3K, Radiosensitizes Head and Neck Squamous Carcinomas Containing Activating PI3KCA Alterations. <i>Clinical Cancer Research</i> , 2016, 22, 2009-2019.	3.2	70
182	Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S): a multicentre cohort study. <i>Lancet Oncology</i> , The, 2016, 17, 440-451.	5.1	607
183	Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. <i>Radiotherapy and Oncology</i> , 2016, 118, 286-292.	0.3	160
184	Feasibility of 18F-Fluoromisonidazole Kinetic Modeling in Head and Neck Cancer Using Shortened Acquisition Times. <i>Journal of Nuclear Medicine</i> , 2016, 57, 334-341.	2.8	16
185	The Influence of Diabetes Mellitus and Metformin on Distant Metastases in Oropharyngeal Cancer: A Multicenter Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 523-531.	0.4	16
186	Long-term patterns of relapse and survival following definitive intensity-modulated radiotherapy for non-endemic nasopharyngeal carcinoma. <i>Oral Oncology</i> , 2016, 53, 67-73.	0.8	44
187	Dose-volume factors correlating with trismus following chemoradiation for head and neck cancer. <i>Acta OncolÃ³gica</i> , 2016, 55, 99-104.	0.8	36
188	Proton Radiation Therapy for Local Control in a Case of Osteosarcoma of the Neck. <i>International Journal of Particle Therapy</i> , 2016, 3, 421-428.	0.9	2
189	Texture analysis on parametric maps derived from dynamic contrast-enhanced magnetic resonance imaging in head and neck cancer. <i>World Journal of Radiology</i> , 2016, 8, 90.	0.5	42
190	Intensity-Modulated Radiation Therapy for Head and Neck Cancer. , 2016, , 301-315.		0
191	Weekly response assessment of involved lymph nodes to radiotherapy using diffusion-weighted MRI in oropharynx squamous cell carcinoma. <i>Medical Physics</i> , 2015, 43, 137-147.	1.6	18
192	Sparing Bilateral Neck Level IB in Oropharyngeal Carcinoma and Xerostomia Outcomes. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 343-347.	0.6	28
193	Irradiation for locoregionally recurrent, never-irradiated oral cavity cancers. <i>Head and Neck</i> , 2015, 37, 1633-1641.	0.9	7
194	Carotid sparing intensity-modulated radiation therapy achieves comparable locoregional control to conventional radiotherapy in T1-2N0 laryngeal carcinoma. <i>Oral Oncology</i> , 2015, 51, 716-723.	0.8	52
195	Radiographic osteoradionecrosis of the jaw with intact mucosa: Proposal of clinical guidelines for early identification of this condition. <i>Oral Oncology</i> , 2015, 51, e93-e96.	0.8	19
196	Palliative head and neck radiotherapy with the RTOG 8502 regimen for incurable primary or metastatic cancers. <i>Oral Oncology</i> , 2015, 51, 957-962.	0.8	67
197	Definitive chemoradiation for primary oral cavity carcinoma: A single institution experience. <i>Oral Oncology</i> , 2015, 51, 709-715.	0.8	29
198	Technology for Innovation in Radiation Oncology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 485-492.	0.4	58

#	ARTICLE	IF	CITATIONS
199	Treatmentâ€related toxicities in older adults with head and neck cancer: A populationâ€based analysis. <i>Cancer</i> , 2015, 121, 2083-2089.	2.0	54
200	A multiâ€institution pooled analysis of gastrostomy tube dependence in patients with oropharyngeal cancer treated with definitive intensityâ€modulated radiotherapy. <i>Cancer</i> , 2015, 121, 294-301.	2.0	109
201	Dorsal vagal complex of the brainstem: Conformal avoidance to reduce nausea In Regard to Monroe et al. <i>Practical Radiation Oncology</i> , 2015, 5, e57.	1.1	1
202	Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. <i>Thyroid</i> , 2015, 25, 567-610.	2.4	1,738
203	Nasopharyngeal Carcinoma. <i>Surgical Oncology Clinics of North America</i> , 2015, 24, 547-561.	0.6	127
204	Detailed Analysis of Clinicopathologic Factors Demonstrate Distinct Difference in Outcome and Prognostic Factors Between Surgically Treated HPV-Positive and Negative Oropharyngeal Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 4411-4421.	0.7	80
205	Squamous cell carcinoma of the tonsil managed by conventional surgery and postoperative radiation. <i>Head and Neck</i> , 2015, 37, 800-807.	0.9	13
206	Nasopharyngeal Cancer. , 2015, , 153-169.		0
207	Hypopharyngeal Carcinoma. <i>Medical Radiology</i> , 2014, , 73-82.	0.0	0
208	Target Delineation of the Neck in Head and Neck Carcinomas. <i>Medical Radiology</i> , 2014, , 147-166.	0.0	0
209	Locally Advanced and Unresectable Cutaneous Squamous Cell Carcinoma: Outcomes of Concurrent Cetuximab and Radiotherapy. <i>Journal of Skin Cancer</i> , 2014, 2014, 1-7.	0.5	37
210	Estimate of the impact of FDG-avidity on the dose required for head and neck radiotherapy local control. <i>Radiotherapy and Oncology</i> , 2014, 111, 340-347.	0.3	38
211	Decision making in the management of recurrent head and neck cancer. <i>Head and Neck</i> , 2014, 36, 144-151.	0.9	153
212	Patterns of failure after salvage re-irradiation for recurrent head and neck cancer: implications for field design and consolidation therapy. <i>Journal of Radiation Oncology</i> , 2014, 3, 139-145.	0.7	3
213	Recommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 390-397.	0.3	126
214	Efficacy of Skin-Directed Therapy for Cutaneous Metastases From Advanced Cancer: A Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 3144-3155.	0.8	131
215	A nomogram to predict loco-regional control after re-irradiation for head and neck cancer. <i>Radiotherapy and Oncology</i> , 2014, 111, 382-387.	0.3	75
216	The relative prognostic utility of standardized uptake value, gross tumor volume, and metabolic tumor volume in oropharyngeal cancer patients treated with platinum based concurrent chemoradiation with a pre-treatment [18F] fluorodeoxyglucose positron emission tomography scan. <i>Oral Oncology</i> , 2014, 50, 802-808.	0.8	34

#	ARTICLE	IF	CITATIONS
217	Patients with low lying lymph nodes are at high risk for distant metastasis in oropharyngeal cancer. <i>Oral Oncology</i> , 2014, 50, 863-868.	0.8	20
218	External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. <i>Journal of Surgical Oncology</i> , 2014, 110, 375-382.	0.8	55
219	Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC). <i>Oral Oncology</i> , 2014, 50, 947-955.	0.8	51
220	Treatment of maxillary sinus cancer in the modern era: one institution's experience. <i>Journal of Radiation Oncology</i> , 2014, 3, 363-369.	0.7	2
221	Why Target the Globe?: 4-year report (2009-2013) of the Association of Residents in Radiation Oncology Global Health Initiative. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 485-491.	0.4	24
222	Results of photon radiotherapy for unresectable salivary gland tumors: is neutron radiotherapy local control superior?. <i>Radiology and Oncology</i> , 2014, 48, 56-61.	0.6	30
223	<i>Cancer of the Head and Neck.</i> , 2014, , 1037-1070.e6.		1
224	Distant metastasis is a critical mode of failure for patients with localized major salivary gland tumors treated with surgery and radiation. <i>Journal of Radiation Oncology</i> , 2013, 2, 285-291.	0.7	3
225	Correlation of planned dose to area postrema and dorsal vagal complex with clinical symptoms of nausea and vomiting in oropharyngeal cancer (OPC) patients treated with radiation alone using IMRT. <i>Journal of Radiation Oncology</i> , 2013, 2, 407-412.	0.7	7
226	High-dose-rate intraoperative brachytherapy and radical surgical resection in the management of recurrent head-and-neck cancer. <i>Brachytherapy</i> , 2013, 12, 228-234.	0.2	29
227	Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma. <i>Radiation Oncology</i> , 2013, 8, 173.	1.2	8
228	<i>Hypopharyngeal Carcinoma.</i> , 2013, , 29-34.		1
229	An International Collaboration to Harmonize the Quantitative Plasma Epstein-Barr Virus DNA Assay for Future Biomarker-Guided Trials in Nasopharyngeal Carcinoma. <i>Clinical Cancer Research</i> , 2013, 19, 2208-2215.	3.2	149
230	Long-term regional control and survival in patients with low-risk, early stage oral tongue cancer managed by partial glossectomy and neck dissection without postoperative radiation. <i>Cancer</i> , 2013, 119, 1168-1176.	2.0	189
231	An Unusual Cause of Isolated Vomiting. <i>Neurology</i> , 2012, 78, 72-73.	1.5	2
232	¹⁸ F-FDG PET/CT Metabolic Tumor Volume and Total Lesion Glycolysis Predict Outcome in Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2012, 53, 1506-1513.	2.8	161
233	Current and emerging treatment options for nasopharyngeal carcinoma. <i>OncoTargets and Therapy</i> , 2012, 5, 297.	1.0	32
234	American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. <i>Thyroid</i> , 2012, 22, 1104-1139.	2.4	717

#	ARTICLE	IF	CITATIONS
235	Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. <i>Lancet Oncology</i> , The, 2012, 13, 172-180.	5.1	291
236	Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 291-298.	0.4	168
237	Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Predictor of Outcome in Head-and-Neck Squamous Cell Carcinoma Patients With Nodal Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1837-1844.	0.4	137
238	Intensity-Modulated Radiation Therapy in Oropharyngeal Carcinoma: Effect of Tumor Volume on Clinical Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1851-1857.	0.4	70
239	New Tracers PET in Head and Neck Squamous Cell Carcinoma. <i>PET Clinics</i> , 2012, 7, 431-441.	1.5	2
240	Dosimetric distribution to the tooth-bearing regions of the mandible following intensity-modulated radiation therapy for base of tongue cancer. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2012, 114, e50-e54.	0.2	45
241	Definitive treatment of metastatic nasopharyngeal carcinoma: Report of 5 cases with review of literature. <i>Head and Neck</i> , 2012, 34, 753-757.	0.9	41
242	Marginal recurrences after selective targeting with intensity-modulated radiotherapy for oral tongue cancer. <i>Head and Neck</i> , 2012, 34, 900-906.	0.9	18
243	Selective radiotherapy for the treatment of head and neck Merkel cell carcinoma. <i>Cancer</i> , 2012, 118, 3937-3944.	2.0	24
244	A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. <i>Cancer</i> , 2012, 118, 5008-5014.	2.0	71
245	Percutaneous endoscopic gastrostomy in oropharyngeal cancer patients treated with intensity-modulated radiotherapy with concurrent chemotherapy. <i>Cancer</i> , 2012, 118, 6072-6078.	2.0	55
246	Intensity-modulated radiation therapy for nasopharyngeal carcinoma: a review. <i>Journal of Radiation Oncology</i> , 2012, 1, 129-146.	0.7	59
247	Concurrent doxorubicin and radiotherapy for anaplastic thyroid cancer: A critical re-evaluation including uniform pathologic review. <i>Radiotherapy and Oncology</i> , 2011, 101, 425-430.	0.3	88
248	Concurrent Cisplatin and Radiation Versus Cetuximab and Radiation for Locally Advanced Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 915-922.	0.4	137
249	Correlation of Osteoradionecrosis and Dental Events With Dosimetric Parameters in Intensity-Modulated Radiation Therapy for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e207-e213.	0.4	114
250	Practical Considerations in the Re-Irradiation of Recurrent and Second Primary Head-and-Neck Cancer: Who, Why, How, and How Much?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 1211-1219.	0.4	74
251	Feasibility of reirradiation of recurrent sinonasal carcinoma in the periorbital region using hypofractionated image-guided intensity-modulated radiation therapy. <i>Head and Neck</i> , 2011, 33, 1372-1378.	0.9	6
252	Hypofractionated Dose-Painting Intensity Modulated Radiation Therapy With Chemotherapy for Nasopharyngeal Carcinoma: A Prospective Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 148-153.	0.4	78

#	ARTICLE	IF	CITATIONS
253	Intensity-Modulated Radiation Therapy for Head and Neck Cancer. , 2011, , 267-279.		0
254	Reirradiation of Locally Recurrent Nasopharynx Cancer With External Beam Radiotherapy With or Without Brachytherapy. International Journal of Radiation Oncology Biology Physics, 2010, 76, 130-137.	0.4	100
255	Noninvasive Assessment of Tumor Microenvironment Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging and 18F-Fluoromisonidazole Positron Emission Tomography Imaging in Neck Nodal Metastases. International Journal of Radiation Oncology Biology Physics, 2010, 77, 1403-1410.	0.4	102
256	High-Dose-Rate Intraoperative Radiation Therapy for Recurrent Head-and-Neck Cancer. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1140-1146.	0.4	32
257	An investigation of intensity-modulated radiation therapy versus conventional two-dimensional and 3D-conformal radiation therapy for early stage larynx cancer. Radiation Oncology, 2010, 5, 74.	1.2	49
258	Pharmacokinetic Analysis of Hypoxia 18F-Fluoromisonidazole Dynamic PET in Head and Neck Cancer. Journal of Nuclear Medicine, 2010, 51, 37-45.	2.8	68
259	Hypoxia Imaging for Image-Guided Radiotherapy. , 2010, , 7-18.		1
260	Cancer of the Larynx. , 2010, , 642-665.		4
261	Cancer of the Hypopharynx. , 2010, , 613-641.		0
262	Cancer of the Nasopharynx. , 2010, , 523-545.		0
263	Concurrent chemotherapy and radiotherapy for head and neck cancer. Expert Review of Anticancer Therapy, 2009, 9, 293-302.	1.1	24
264	Head-and-Neck Target Delineation Among Radiation Oncology Residents After a Teaching Intervention: A Prospective, Blinded Pilot Study. International Journal of Radiation Oncology Biology Physics, 2009, 73, 416-423.	0.4	57
265	Role of External Beam Radiotherapy in Patients With Advanced or Recurrent Nonanaplastic Thyroid Cancer: Memorial Sloan-Kettering Cancer Center Experience. International Journal of Radiation Oncology Biology Physics, 2009, 73, 795-801.	0.4	127
266	Intensity-Modulated Radiotherapy in Postoperative Treatment of Oral Cavity Cancers. International Journal of Radiation Oncology Biology Physics, 2009, 73, 1096-1103.	0.4	109
267	Prospective Trial Incorporating Pre-/Mid-Treatment [18F]-Misonidazole Positron Emission Tomography for Head-and-Neck Cancer Patients Undergoing Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 75, 101-108.	0.4	126
268	PET Monitoring of Therapy Response in Head and Neck Squamous Cell Carcinoma. Journal of Nuclear Medicine, 2009, 50, 74S-88S.	2.8	172
269	Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Physics in Medicine and Biology, 2009, 54, 3083-3099.	1.6	61
270	Intensity-Modulated Radiation Therapy With or Without Chemotherapy for Nasopharyngeal Carcinoma: Radiation Therapy Oncology Group Phase II Trial 0225. Journal of Clinical Oncology, 2009, 27, 3684-3690.	0.8	607

#	ARTICLE	IF	CITATIONS
271	Severe Radiation Dermatitis in Patients With Locally Advanced Head and Neck Cancer Treated With Concurrent Radiation and Cetuximab. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 472-476.	0.6	29
272	Merkel Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2009, 7, 322-332.	2.3	70
273	Intensity-modulated chemoradiation for treatment of stage III and IV oropharyngeal carcinoma. <i>Cancer</i> , 2008, 113, 497-507.	2.0	130
274	Postoperative intensity-modulated radiation therapy for cancers of the paranasal sinuses, nasal cavity, and lacrimal glands: Technique, early outcomes, and toxicity. <i>Head and Neck</i> , 2008, 30, 925-932.	0.9	46
275	Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 2-13.	0.4	220
276	Intensity-Modulated Radiotherapy for Head and Neck Cancer of Unknown Primary: Toxicity and Preliminary Efficacy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1100-1107.	0.4	72
277	Outcomes and Prognostic Variables in Adenoid Cystic Carcinoma of the Head and Neck: A Recent Experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1365-1372.	0.4	122
278	Reproducibility of Intratumor Distribution of 18F-Fluoromisonidazole in Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 235-242.	0.4	209
279	Recurrence in Region of Spared Parotid Gland After Definitive Intensity-Modulated Radiotherapy for Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 660-665.	0.4	139
280	The Influence of Changes in Tumor Hypoxia on Dose-Painting Treatment Plans Based on 18F-FMISO Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 70, 1219-1228.	0.4	168
281	Unresectable Carcinoma of the Paranasal Sinuses: Outcomes and Toxicities. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 763-769.	0.4	82
282	Development and Validation of a Standardized Method for Contouring the Brachial Plexus: Preliminary Dosimetric Analysis Among Patients Treated With IMRT for Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1362-1367.	0.4	129
283	New Developments in Radiation Therapy for Head and Neck Cancer: Intensity-Modulated Radiation Therapy and Hypoxia Targeting. <i>Seminars in Oncology</i> , 2008, 35, 236-250.	0.8	39
284	Treatment outcomes for patients with synovial sarcoma of the head and neck. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 371-373.	1.1	30
285	Evaluation of Different Methods of 18F-FDG-PET Target Volume Delineation in the Radiotherapy of Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2008, 31, 439-445.	0.6	38
286	A Unique Complication Associated with Concurrent Chemoradiation for the Treatment of Locally Advanced Head and Neck Cancer. <i>Clinical Medicine Oncology</i> , 2008, 2, CMO.S407.	0.2	0
287	Intensity-Modulated Radiation Therapy for Head and Neck Carcinoma. <i>Oncologist</i> , 2007, 12, 555-564.	1.9	106
288	Simplifying intensity-modulated radiotherapy plans with fewer beam angles for the treatment of oropharyngeal carcinoma. <i>Journal of Applied Clinical Medical Physics</i> , 2007, 8, 26-36.	0.8	7

#	ARTICLE	IF	CITATIONS
289	Using an onboard kilovoltage imager to measure setup deviation in intensity-modulated radiation therapy for head-and-neck patients. <i>Journal of Applied Clinical Medical Physics</i> , 2007, 8, 28-44.	0.8	23
290	Intensity-modulated radiation therapy in head and neck cancers: An update. <i>Head and Neck</i> , 2007, 29, 387-400.	0.9	175
291	Treatment of nasal cavity and paranasal sinus cancer with modern radiotherapy techniques in the postoperative setting—the MSKCC experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 691-702.	0.4	213
292	Patterns of nodal relapse after surgery and postoperative radiation therapy for carcinomas of the major and minor salivary glands: What is the role of elective neck irradiation?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 988-994.	0.4	116
293	Choosing an Intensity-Modulated Radiation Therapy Technique in the Treatment of Head-and-Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1299-1309.	0.4	53
294	Salvage Re-Irradiation for Recurrent Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 731-740.	0.4	235
295	Carcinomas of the Paranasal Sinuses and Nasal Cavity Treated With Radiotherapy at a Single Institution Over Five Decades: Are We Making Improvement?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 141-147.	0.4	132
296	Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Locoregionally Advanced Laryngeal and Hypopharyngeal Cancers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 459-468.	0.4	126
297	Intensity-Modulated Radiation Therapy in the Treatment of Head and Neck Cancer Involving the Base of the Skull. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, S43-S45.	0.4	4
298	In Reply to Dr. Nieder. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1653.	0.4	0
299	Results of Surgical Salvage After Failure of Definitive Radiation Therapy for Early-Stage Squamous Cell Carcinoma of the Glottic Larynx. <i>JAMA Otolaryngology</i> , 2006, 132, 59.	1.5	139
300	Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 363-373.	0.4	272
301	Geometric factors influencing dosimetric sparing of the parotid glands using IMRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 296-304.	0.4	71
302	A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 966-974.	0.4	146
303	The role of external beam radiotherapy in the treatment of papillary thyroid cancer. <i>Endocrine-Related Cancer</i> , 2006, 13, 971-977.	1.6	52
304	IMRT for Carcinomas of the Nasopharynx. , 2006, , 319-334.		0
305	Intensity-Modulated Radiation Therapy in Head and Neck Cancers. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2005, 28, 415-423.	0.6	54
306	Advances in nasopharyngeal carcinoma. <i>Current Opinion in Oncology</i> , 2005, 17, 225-230.	1.1	16

#	ARTICLE	IF	CITATIONS
307	Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 1419-1426.	0.4	74
308	Counterpoint. <i>Brachytherapy</i> , 2005, 4, 5-7.	0.2	5
309	Intensity-modulated radiation therapy for head and neck cancer. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 515-521.	1.1	9
310	A forward-planned treatment technique using multisegments in the treatment of head-and-neck cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 584-594.	0.4	28
311	In response to Drs. Yao, Dornfeld, and Buatti: the importance of target volume delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1639-1640.	0.4	2
312	A study of planning dose constraints for treatment of nasopharyngeal carcinoma using a commercial inverse treatment planning system. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 59, 886-896.	0.4	26
313	Postoperative Concurrent Radiotherapy and Chemotherapy for High-Risk Squamous-Cell Carcinoma of the Head and Neck. <i>New England Journal of Medicine</i> , 2004, 350, 1937-1944.	13.9	2,756
314	Gamma knife radiosurgery for recurrent salivary gland malignancies involving the base of skull. <i>Head and Neck</i> , 2003, 25, 210-216.	0.9	33
315	Comparison of treatment plans using intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for paranasal sinus carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 56, 158-168.	0.4	78
316	Intensity-modulated radiation therapy for head-and-neck cancer: The UCSF experience focusing on target volume delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 49-60.	0.4	272
317	CT-based delineation of lymph node levels and related CTVs in the node-negative neck: DAHANCA, EORTC, GORTEC, NCIC, RTOG consensus guidelines. <i>Radiotherapy and Oncology</i> , 2003, 69, 227-236.	0.3	611
318	Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 12-22.	0.4	924
319	Skin toxicity due to intensity-modulated radiotherapy for head-and-neck carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 53, 630-637.	0.4	214
320	Managing nasopharyngeal carcinoma with intracavitary brachytherapy. <i>Brachytherapy</i> , 2002, 1, 74-82.	0.2	26
321	Nasopharyngeal Cancer. <i>Medical Radiology</i> , 0, , 17-36.	0.0	1
322	Association of Low and Intermediate Combined Positive Scores With Outcomes of Treatment With Pembrolizumab in Patients With Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma. <i>JAMA Oncology</i> , 0, , .	3.4	4
323	Comparison of Objective Measures of Trismus and Salivation With Patient-reported Outcomes Following Treatment for Head and Neck Cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 0, , .	1.2	2